- Conditions
- Persistent Asthma
- Interventions
- Indacaterol, Placebo to Indacaterol
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 191 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 21
- States / cities
- Anniston, Alabama • Cypress, California • Fresno, California + 16 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Osteoarthritis
- Interventions
- Bone Marrow Derived MSCs, Adipose-derived MSCs, Umbilical Cord Tissue (UCT) MSCs, Corticosteroid injection
- Biological · Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 40 Years to 70 Years
- Enrollment
- 475 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 5
- States / cities
- Gulf Breeze, Florida • Atlanta, Georgia • Durham, North Carolina + 2 more
- Conditions
- Legg-Calve Perthes Disease
- Interventions
- Aristospan 20mg
- Drug
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 4 Years to 13 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Asthma
- Interventions
- Indacaterol, Salmeterol, Placebo to Indacaterol, Placebo to Salmeterol
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 511 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 71
- States / cities
- Glendale, Arizona • Scottsdale, Arizona • Encinitas, California + 64 more
- Conditions
- Thigh Muscle Injury, Thigh Injury, Musculoskeletal, Musculoskeletal Injury Trauma, Musculoskeletal Injuries
- Interventions
- Corticosteroid, Platelet Poor Plasma
- Drug · Biological
- Lead sponsor
- Andrews Research & Education Foundation
- Other
- Eligibility
- 15 Years to 30 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Gulf Breeze, Florida
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Indacaterol 150 μg, Placebo to indacaterol
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 416 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 118
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Jasper, Alabama + 105 more
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Indacaterol 150 μg, Tiotropium 18 μg, Placebo to indacaterol
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 1,142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 116
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Jasper, Alabama + 102 more
- Conditions
- Graft Vs Host Disease, Acute-graft-versus-host Disease, Chronic Graft-versus-host-disease
- Interventions
- Exercise, Attention control
- Behavioral
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Asthma
- Interventions
- Indacaterol 300 μg, Salmeterol 50 μg, Placebo to indacaterol, Placebo to salmeterol
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 805 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 56
- States / cities
- Glendale, Arizona • Phoenix, Arizona • Encinitas, California + 44 more
- Conditions
- Medication Adherence, Asthma in Children
- Interventions
- Nominal Financial Incentives, Daily Adherence Reminders/Adherence Performance Feedback
- Other
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 5 Years to 12 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Vitreo-Retinal Surgery
- Interventions
- Dextenza 0.4Mg Ophthalmic Insert, Topical Prednisolone
- Drug
- Lead sponsor
- Patrick R. Oellers, MD
- Network
- Eligibility
- Not listed
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Liverpool, New York
- Conditions
- Community-acquired Pneumonia, Influenza, COVID-19
- Interventions
- Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
- Drug · Other · Biological + 1 more
- Lead sponsor
- UMC Utrecht
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 11
- States / cities
- Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
- Conditions
- Asthma
- Interventions
- Symbicort pMDI, budesonide pMDI
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 12 Years to 130 Years
- Enrollment
- 12,460 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 160
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 157 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Indacaterol 300 μg, Placebo to indacaterol, Salmeterol 50 μg
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 7
- States / cities
- Normal, Illinois • Shawnee Mission, Kansas • Lafayette, Louisiana + 4 more
- Conditions
- Chronic Lateral Epicondylosis
- Interventions
- Platelet Rich Plasma - Group 1, Corticosteroid Control - Group 2
- Biological · Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome), CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), Prolymphocyctic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasm (MPN), Lymphoma, Myelofibrosis
- Interventions
- Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E, Hematopoietic Cell Transplantation, PTCy (50 mg/kg D3, D4), PTCy (25 mg/kg D3, D4), Post-transplant Tacrolimus, Post-transplant Mycophenolate mofetil, Post-transplant Abatacept, Post-transplant Ruxolitinib, Supportive Care: Growth Factors, Supportive Care: Blood Products, Supportive Care: Infection Prophylaxis, Supportive Care: Intravenous immune globulin (IVIG), Supportive Care: Seizure prophylaxis, Supportive Care: Monitoring and management of CRS, Supportive Care: Prophylaxis against infections, Supportive Care: Prophylaxis against infections, Supportive Care: Lipid elevations, Study treatment compliance, Prohibited Concomitant Therapy, Permitted Concomitant Therapy
- Drug · Procedure · Other
- Lead sponsor
- Center for International Blood and Marrow Transplant Research
- Network
- Eligibility
- 18 Years to 66 Years
- Enrollment
- 358 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more
- Conditions
- Myocarditis Acute
- Interventions
- Methylprednisolone, saline solution
- Drug
- Lead sponsor
- Niguarda Hospital
- Other
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 288 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 4
- States / cities
- San Diego, California • Houston, Texas • Charlottesville, Virginia + 1 more
- Conditions
- Asthma
- Interventions
- GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS)
- Biological · Drug · Device
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,717 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 119
- States / cities
- Birmingham, Alabama • Scottsboro, Alabama • Litchfield Park, Arizona + 94 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Placebo ELLIPTA, Nemiralisib ELLIPTA 50 µg, Nemiralisib ELLIPTA 100 µg, Nemiralisib ELLIPTA 250 µg, Nemiralisib ELLIPTA 500 µg, Nemiralisib ELLIPTA 750 µg, Albuterol (Salbutamol) MDI or nebules, Standard of care therapy
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 943 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 21
- States / cities
- Mobile, Alabama • Colorado Springs, Colorado • Daytona Beach, Florida + 17 more
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Indacaterol 150 μg, Tiotropium 18 μg, Placebo to indacaterol
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 1,134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 61
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 53 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Indacaterol, Placebo to indacaterol
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 318 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 54
- States / cities
- Anniston, Alabama • Jasper, Alabama • Glendale, Arizona + 46 more
- Conditions
- Renal Transplant
- Interventions
- Sirolimus
- Drug
- Lead sponsor
- Pediatric Nephrology of Alabama
- Other
- Eligibility
- Up to 19 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • Los Angeles, California • Stanford, California + 1 more
- Conditions
- Duchenne Muscular Dystrophy (DMD)
- Interventions
- Prednisone, Exercise Training on standard steroid regimen, Exercise training on twice-weekly steroids
- Drug · Behavioral
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 5 Years to 9 Years · Male only
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Ornithine Transcarbamylase (OTC) Deficiency
- Interventions
- scAAV8OTC, Reactive Corticosteroid Taper Regimen, Prophylactic Corticosteroid Taper Regimen
- Genetic · Drug
- Lead sponsor
- Ultragenyx Pharmaceutical Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Boston, Massachusetts • New York, New York + 1 more